Radiation therapy is an important component of cancer therapy for many malignancies. With
improvements in cardiac-sparing techniques, radiation-induced cardiac dysfunction has …

Since the 1960s, paediatric oncologists have gradually become better organised in large
study groups and participation in clinical trials is today considered as the standard of care …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …

Objective To systematically review and perform a meta-analysis of radiation associated risks
of cardiovascular disease in all groups exposed to radiation with individual radiation dose …

Survivors of childhood, adolescent, and young adult cancer, previously treated with
anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was …

Research about heart failure (HF) has made major progress in the last years. We give here
an update on the most recent findings. Landmark trials have established new treatments for …

Advances in cancer treatments have improved clinical outcomes, leading to an increasing
population of cancer survivors. However, this success is associated with high rates of short …

Dose constraints are essential for performing dosimetry, especially for intensity modulation
and for radiotherapy under stereotaxic conditions. We present the update of the …

Cardiac diseases in the growing population of childhood cancer survivors are of major
concern. Cardiotoxicity as a consequence of anthracyclines and chest radiotherapy …

Survivors of childhood cancer are at risk of anthracycline-induced cardiotoxicity, which might
be prevented by dexrazoxane. However, concerns exist about the safety of dexrazoxane …